Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032

BACKGROUND: BRAFV600E mutation is the most common mutation in thyroid cancer. It strongly activates MAPK/ERK pathway and indicates an invasive subtype of thyroid cancer. PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Exp Clin Cancer Res
Päätekijät: Su, Xi, Li, Peng, Han, Bin, Jia, Hao, Liang, Qingzhuang, Wang, Haichao, Gu, Mengwei, Cai, Jiaxuan, Li, Shaolei, Zhou, Yaqi, Yi, Xin, Wei, Wei
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2021
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7816401/
https://ncbi.nlm.nih.gov/pubmed/33468157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-01831-y
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia